[Ip-health] Politico: Gavi proposes scheme to ensure accessible COVID-19 vaccine supply (amc)

Dimitri Eynikel Dimitri.Eynikel at msf.org
Tue May 5 03:04:13 PDT 2020


apologies for cross posting
Best,
Dimitri

https://pro.politico.eu/news/118638

politico:

Gavi proposes scheme to ensure accessible COVID-19 vaccine supply
by Carlo Martuscelli<https://pro.politico.eu/authors/5496>
May 4, 2020, 8:54 PM

The head of Gavi, which promotes vaccine access in poor countries, today proposed setting up a scheme to incentivize industry to supply an affordable vaccine for COVID-19.

Speaking at the European Commission's pledging conference<https://pro.politico.eu/news/118633>, Chief Executive Seth Berkley said that an Advance Market Commitment program would help manage supply and demand for an eventual COVID-19 vaccine, allowing for scaled-up manufacture and availability.

The idea, explained in greater length in a written statement<https://www.gavi.org/vaccineswork/what-advance-market-commitment-and-how-could-it-help-beat-covid-19> by Gavi, involves incentivizing vaccine makers by agreeing to buy large amounts of a vaccine at a set price. This ensures that companies developing a vaccine know that they have a market for it and can price the vaccine at a level that is widely accessible.

Gavi, the Vaccine Alliance, points to the success of a similar program for pneumococcal vaccines<https://www.gavi.org/investing-gavi/innovative-financing/pneumococcal-amc> as providing a template for future action. However, due to the scale of the coronavirus pandemic, the organization notes that funds will also need to be invested in beefing up manufacturing capacity and securing raw materials.

Dimitri Eynikel, access campaign EU policy adviser at Doctors Without Borders (MSF), suggested caution, citing precisely the pneumococcal campaign. "It hasn't always delivered quantities of vaccines that were needed," he explained.

There was also the risk that the mechanism would leave those using it overly-reliant on a select few vaccine manufacturers, particularly when compared with a solution that involved a greater number of producers.

For now, there is a lack of detail on how an eventual scheme will be designed, but it will be these details that determine whether it works or not, Eynikel added.


Coronavirus<https://pro.politico.eu/tag/coronavirus>Drug pricing<https://pro.politico.eu/tag/drug-pricing>Global health<https://pro.politico.eu/tag/global-health>Infectious diseases<https://pro.politico.eu/tag/infectious-diseases>Medicines<https://pro.politico.eu/tag/medicines>Pharma<https://pro.politico.eu/tag/pharma>Public health<https://pro.politico.eu/tag/public-health>Vaccines<https://pro.politico.eu/tag/vaccines>European Commission<https://pro.politico.eu/tag/european-commission>
Send to mePrint






More information about the Ip-health mailing list